RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer

Journal of Controlled Release

Volumn 196, Issue , 2014, Pages 222-233

  Wang, Fangfang ^a   Chen, Lei ^a   Zhang, Rui ^a   Chen, Zhongping ^a   Zhu, Li ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

bone metastasis; cisplatin; drug delivery; integrin; liposome; RGD peptide

Indexed keywords

LIPOSOMES;

BONE METASTASIS; CIS-PLATIN; INTEGRINS; LIPOSOMAL DRUG DELIVERY SYSTEMS; PROSTATE CANCERS; RGD PEPTIDE; THERAPEUTIC EFFICACY;

DRUG DELIVERY;

ARGINYLGLYCYLASPARTIC ACID; CISPLATIN; LIPOSOME; VITRONECTIN RECEPTOR; ANTINEOPLASTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; OLIGOPEPTIDE; QUANTUM DOT; SULFIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BONE PAIN; CIRCULATION TIME; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROSTATE CANCER; TISSUE DISTRIBUTION; ANIMAL; BONE NEOPLASMS; C57BL MOUSE; CELL LINE; CHEMISTRY; HUMAN; INFRARED RADIATION; MALE; PAIN; PARTICLE SIZE; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; SECONDARY; SURVIVAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL LINE; CISPLATIN; DRUG DELIVERY SYSTEMS; HUMANS; INFRARED RAYS; LIPOSOMES; MALE; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; PAIN; PARTICLE SIZE; PROSTATIC NEOPLASMS; QUANTUM DOTS; SULFIDES; SURVIVAL ANALYSIS;

EID: 84908462206     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.10.012     Document Type: Article

References (48)

1. G.R. Mundy Metastasis to bone: causes, consequences and therapeutic opportunities Nat. Rev. Cancer 2 2002 584 593
2. R.E. Coleman Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat. Rev. 27 2001 165 176
3. M. Kawatani, and H. Osada Osteoclast-targeting small molecules for the treatment of neoplastic bone metastases Cancer Sci. 100 2009 1999 2005
4. A. Lipton Implications of bone metastases and the benefits of bone-targeted therapy Semin. Oncol. 37 Suppl. 2 2010 S15 S29
5. A. Lipton New strategies to prevent and manage bone complications in cancer Clin. Adv. Hematol. Oncol. 9 2011 42 44
6. K.D. Brubaker, L.G. Brown, R.L. Vessella, and E. Corey Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment BMC Cancer 6 2006
7. S.A. Low, and J. Kopecek Targeting polymer therapeutics to bone Adv. Drug Deliv. Rev. 64 2012 1189 1204
8. P. Clezardin Therapeutic targets for bone metastases in breast cancer Breast Cancer Res. 13 2011
9. M. Esposito, and Y.B. Kang Targeting tumor-stromal interactions in bone metastasis Pharmacol. Therapeut. 141 2014 222 233
10. T. Klenner, F. Wingen, B.K. Keppler, B. Krempien, and D. Schmahl Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies? J. Cancer Res. Clin. Oncol. 116 1990 341 350
11. O. Fabulet, and G. Sturtz Synthesis of gem-bisphosphonic doxorubicin conjugates Phosphorus Sulfur Silicon Relat. Elem. 101 1995 225 234
12. A. Schroeder, D.A. Heller, M.M. Winslow, J.E. Dahlman, G.W. Pratt, and R. Langer Treating metastatic cancer with nanotechnology Nat. Rev. Cancer 12 2012 39 50
13. K.R. Chaudhari, A. Kumar, V.K.M. Khandelwal, A.K. Mishra, J. Monkkonen, and R.S.R. Murthy Targeting efficiency and biodistribution of zoledronate conjugated docetaxel loaded pegylated PBCA nanoparticles for bone metastasis Adv. Funct. Mater. 22 2012 4101 4114
14. K. Ramanlal Chaudhari, A. Kumar, V.K. Megraj Khandelwal, M. Ukawala, A.S. Manjappa, and A.K. Mishra Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel J. Control. Release 158 2012 470 478
15. S.I. Thamake, S.L. Raut, Z. Gryczynski, A.P. Ranjan, and J.K. Vishwanatha Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer Biomaterials 33 2012 7164 7173
16. S.-W. Choi, and J.-H. Kim Design of surface-modified poly (D, L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone J. Control. Release 122 2007 24 30
17. B. Chi, S.J. Park, M.H. Park, S.Y. Lee, and B. Jeong Oligopeptide Delivery Carrier for Osteoclast Precursors Bioconjug. Chem. 21 2010 1473 1478
18. A.P. Mann, T. Tanaka, A. Somasunderam, X. Liu, D.G. Gorenstein, and M. Ferrari E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow Adv. Mater. 23 2011 H278 H282
19. J.S. Desgrosellier, and D.A. Cheresh Integrins in cancer: biological implications and therapeutic opportunities Nat. Rev. Cancer 10 2010 9 22
20. N. McCabe, S. De, A. Vasanji, J. Brainard, and T. Byzova Prostate cancer specific integrin αvβ3 modulates bone metastatic growth and tissue remodeling Oncogene 26 2007 6238 6243
21. J.G. Schneider, S.R. Amend, and K.N. Weilbaecher Integrins and bone metastasis: integrating tumor cell and stromal cell interactions Bone 48 2011 54 65
22. S.J. Bakewell, P. Nestor, S. Prasad, M.H. Tomasson, N. Dowland, and M. Mehrotra Platelet and osteoclast beta(3) integrins are critical for bone metastasis Proc. Natl. Acad. Sci. 100 2003 14205 14210
23. M. Sutherland, A. Gordon, S.D. Shnyder, L.H. Patterson, and H.M. Sheldrake RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis Cancers (Basel) 4 2012 1106 1145
24. A. Accardo, D. Tesauro, and G. Morelli Peptide-based targeting strategies for simultaneous imaging and therapy with nanovectors Polym. J. 45 2013 481 493
25. R.M. Levine, C.M. Scott, and E. Kokkoli Peptide functionalized nanoparticles for nonviral gene delivery Soft Matter 9 2013 985 1004
26. P. Liu, L. Qin, Q. Wang, Y. Sun, M. Zhu, and M. Shen cRGD-functionalized mPEG-PLGA-PLL nanoparticles for imaging and therapy of breast cancer Biomaterials 33 2012 6739 6747
27. W.B. Cai, X.Q. Yang, H. Hong, J.J. Grailer, I.J. Rowland, and A. Javadi cRGD-functionalized, DOX-conjugated, and (64)Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging Biomaterials 32 2011 4151 4160
28. C.-W. Chen, D.-W. Lu, M.-K. Yeh, C.-Y. Shiau, and C.-H. Chiang Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells Int. J. Nanomedicine 6 2011 2567 2580
29. E.M. Kim, M.H. Jeong, D.W. Kim, H.J. Jeong, S.T. Lim, and M.H. Sohn Iodine 125-labeled mesenchymal-epithelial transition factor binding peptide-click-cRGDyk heterodimer for glioma imaging Cancer Sci. 102 2011 1516 1521
30. W.T. Al-Jamal, K.T. Al-Jamal, P.H. Bomans, P.M. Frederik, and K. Kostarelos Functionalized-quantum-dot-liposome hybrids as multimodal nanoparticles for cancer Small 4 2008 1406 1415
31. V.K. Yellepeddi, A. Kumar, D.M. Maher, S.C. Chauhan, K.K. Vangara, and S. Palakurthi Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT Anticancer Res. 31 2011 897 906
32. Q. Zheng, D. Fang, J. Cai, Y. Wan, J.S. Han, and G.G. Xing Enhanced excitability of small dorsal root ganglion neurons in rats with bone cancer pain Mol. Pain 8 2012 24
33. F. Wang, Z. Chen, and L. Zhu cRGD-conjugated magnetic-fluorescent liposomes for targeted dual-modality imaging of bone metastasis from prostate cancer J. Liposome Res. 2014 10.3109/08982104.2014.928890
34. H. Vermeirsch, R.M. Nuydens, P.L. Salmon, and T.F. Meert Bone cancer pain model in mice: evaluation of pain behavior, bone destruction and morphine sensitivity Pharmacol. Biochem. Behav. 79 2004 243 251
35. J. Gubernator, G. Chwastek, M. Korycinska, M. Stasiuk, G. Grynkiewicz, and F. Lewrick The encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivo J. Control. Release 146 2010 68 75
36. M. Swierczewska, S. Lee, and X.Y. Chen The design and application of fluorophore-gold nanoparticle activatable probes Phys. Chem. Chem. Phys. 13 2011 9929 9941
37. L. Josephson, M.F. Kircher, U. Mahmood, Y. Tang, and R. Weissleder Near-Infrared Fluorescent Nanoparticles as Combined MR/Optical Imaging Probes Bioconjug. Chem. 13 2002 554 560
38. C.F. Chiu, N. Dementev, and E. Borguet Fluorescence Quenching of Dyes Covalently Attached to Single-Walled Carbon Nanotubes J. Phys. Chem. A 115 2011 9579 9584
39. X. Zeng, W. Tao, L. Mei, L. Huang, C. Tan, and S.S. Feng Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer Biomaterials 34 2013 6058 6067
40. Y.F. Yang, Y. Yang, X.Y. Xie, X.S. Cai, H. Zhang, and W. Gong PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy Biomaterials 35 2014 4368 4381
41. P. Sautot, M. Tarek, M.-J. Stébé, C. Paris, E. Arab-Tehrany, and M. Linder Structural, hydration, and phase transition properties of phosphatidylcholine from salmon heads Eur. J. Lipid Sci. Technol. 113 2011 744 755
42. L.A. Bareford, and P.W. Swaan Endocytic mechanisms for targeted drug delivery Adv. Drug Deliv. Rev. 59 2007 748 758
43. Z. Chen, J. Deng, Y. Zhao, and T. Tao Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats Int. J. Nanomed. 7 2012 3803 3811
44. J. Glendenning, and G. Cook Imaging breast cancer bone metastases: current status and future directions Semin. Nucl. Med. 43 2013 317 323
45. G.L. Currie, A. Delaney, M.I. Bennett, A.H. Dickenson, K.J. Egan, and H.M. Vesterinen Animal models of bone cancer pain: Systematic review and meta-analyses Pain 154 2013 917 926
46. H. Maeda, H. Nakamura, and J. Fang The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo Adv. Drug Deliv. Rev. 65 2013 71 79
47. J.T. Buijs, C.C.H.J. Kuijpers, and G. van der Pluijm Targeted Therapy Options for Treatment of Bone Metastases; Beyond Bisphosphonates Curr. Pharm. Des. 16 2010 3015 3027
48. J.C.M. Clark, C.R. Dass, and P.F.M. Choong Current and future treatments of bone metastases Expert Opin. Emerg. Drugs. 13 2008 609 627